tbuckley/cabot-search huggingface dataset:
Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy
Authors: Marjolein J.E. Greuter, Clasine M. de Klerk, Gerrit A. Meijer, Evelien Dekker, Veerle M.H. Coupé
Journal: Annals of Internal Medicine (2017)

Background: Population-based screening to prevent colorectal cancer (CRC) death is effective, but the effectiveness of postpolypectomy surveillance is unclear. Objective: To evaluate the additional benefit in terms of cost-effectiveness of colonoscopy surveillance in a screening setting. Design: Microsimulation using the ASCCA (Adenoma and Serrated pathway to Colorectal CAncer) model. Data Sources: Dutch CRC screening program and published literature. Target Population: Asymptomatic persons aged 55 to 75 years without a prior CRC diagnosis. Time Horizon: Lifetime. Perspective: Health care payer. Intervention: Fecal immunochemical test (FIT) screening with colonoscopy surveillance performed according to the Dutch guideline was simulated. The comparator was no screening or surveillance. FIT screening without colonoscopy surveillance and the effect of extending surveillance intervals were also evaluated. Outcome Measures: CRC burden, colonoscopy demand, life-years, and costs. Results of Base-Case Analysis: FIT screening without surveillance reduced CRC mortality by 50.4% compared with no screening or surveillance. Adding surveillance to FIT screening reduced mortality by an additional 1.7% to 52.1% but increased lifetime colonoscopy demand by 62% (from 335 to 543 colonoscopies per 1000 persons) at an additional cost of €68 000, for an increase of 0.9 life-year. Extending the surveillance intervals to 5 years reduced CRC mortality by 51.8% and increased colonoscopy demand by 42.7% compared with FIT screening without surveillance. In an incremental analysis, incremental cost-effectiveness ratios (ICERs) for screening plus surveillance exceeded the Dutch willingness-to-pay threshold of €36 602 per life-year gained. Results of Sensitivity Analysis: When using a parameter set representing low colorectal lesion prevalence or when colonoscopy costs were halved or colorectal lesion incidence was doubled, screening plus surveillance became cost-effective compared with screening without surveillance. Limitation: Limited data on FIT performance and background CRC risk in the surveillance population. Conclusion: Adding surveillance to FIT screening is not cost-effective based on the Dutch ICER threshold and substantially increases colonoscopy demand. Extending surveillance intervals to 5 years would decrease colonoscopy demand without substantial loss of effectiveness. Primary Funding Source: Alpe d'HuZes, Dutch Cancer Society, and Stand Up To Cancer.
Optic Nerve Infiltration in Primary Central Nervous System Lymphoma
Authors: Guido Ahle, Valérie Touitou, Nathalie Cassoux, Marie Bouyon, Catherine Humbrecht, Hélène Oesterlé, Alexander Baraniskin, Carole Soussain, Ludovic Nguyen-Them, Claude Gaultier, Khê Hoang-Xuan, Caroline Houillier
Journal: JAMA Neurology (2017)

Visual impairment in primary central nervous system lymphoma (PCNSL) is caused mostly by intraocular lymphomatous involvement (vitritis and retinal infiltration), whereas optic nerve infiltration (ONI) is a rare condition.To describe the clinical presentation of ONI, its imaging characteristics, and outcome.A total of 752 patients diagnosed with PCNSL were retrospectively identified from the databases of 3 French hospitals from January 1, 1998, through December 31, 2014. Of these, 7 patients had documented ONI. Exclusion criteria were intraocular involvement, orbital lymphoma, or other systemic lymphoma. Clinical presentation, neuroimaging, biological features, treatment, and outcomes were assessed.Treatment response was evaluated clinically and radiologically on follow-up magnetic resonance imaging (MRI) according to the International PCNSL Collaborative Group response criteria.The 7 patients included 5 women and 2 men. Median age at diagnosis was 65 years (range, 49-78 years). Two patients had initial ONI at diagnosis, and 5 had ONI at relapse. Clinical presentation was marked by rapidly progressive and severe visual impairment for all patients. The MRI findings showed optic nerve enlargement in 3 patients and contrast enhancement of the optic nerve in all patients. Additional CNS lesions were seen in 4 patients. Examination of cerebrospinal fluid samples detected lymphomatous meningitis in 2 patients. Clinical outcome was poor and marked by partial recovery for 2 patients and persistent severe low visual acuity or blindness for 5 patients. Median progression-free survival after optic nerve infiltration was 11 months (95% CI, 9-13 months), and median overall survival was 18 months (95% CI, 9-27 months).Optic nerve infiltration is an atypical and challenging presentation of PCNSL. Its visual and systemic prognosis is particularly poor compared with vitreoretinal lymphomas even in response to chemotherapy. Although intraocular involvement is frequent in PCNSL and clinically marked by slowly progressive visual deterioration, lymphomatous ONI is rare and characterized by rapidly progressive severe visual impairment.
Abstract 14799: Over-expression of Telomerase Reverse Transcriptase Increases Self-renewal, Survival and Multi-potency in Human Cardiac Progenitor Cells Derived From Aged and Diseased Hearts
Authors: Thi Y Le, Hilda A Pickett, Melad Farraha, Cris dos Remedios, James J Chong
Journal: Circulation (2016)

Introduction: Stem cells, or their derivatives, are an exciting potential treatment for heart failure. We have recently characterised a resident cardiac progenitor cell population, named cardiac co...
Epidemia di gastroenterite da virus Norwalk-like in una casa di riposo a Rotterdam
Authors: O Ronveaux, D Vos, A Bosman, K Brandwijk, J Vinjé, M Koopmans, R Reintjes
Journal: Eurosurveillance (2000)

Il 62% (74/120) dei pazienti anziani e disabili di una casa di riposo nei Paesi Bassi e il 32% del personale (33/102) si sono ammalati nel corso di un'epidemia di gastroenterite da virus Norwalk-like. La diffusione dell'epidemia da persona a persona e stata facilitata dal temporaneo raggruppamento dei casi. L'essere nutriti dal personale e stato associato a tassi d'attacco piu elevati.
Early Brain Imaging in Infants May Help Predict Autism
Authors: Tracy Hampton
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
There’s no such thing as an unnecessary referral
Authors: Andrew N Bamji
Journal: BMJ (2017)

I know whether good GPs refer less, or bad GPs refer more,1 because I studied this subject nearly 25 years ago, analysing one year’s worth of new patients (over 600). A tiny number of GPs regularly made “bad” referrals (often because they hadn’t examined the patient), but “excellent” GPs sometimes made referrals that seemed unnecessary.

But how do you …
Planos pandémicos contra a gripe na Europa: história e princípios
Authors: C Hannoun
Journal: Eurosurveillance (1998)

A gripe espanhola de 1918-1919 afectou, virtualmente, todas as familias. O alivio sentido pelo final de uma guerra mundial atroz foi substituido por um flagelo fulminante que reclamou mais de 20 milhoes de vitimas. A gripe, cujas formas epidemicas diferem quanto a severidade (quadro 1), causa por vezes, flagelos terriveis.
GW28-e0580 Management of right-side aortic arch coexisted with aortic dissection
Authors: Huanyu Ding, Minchun Jiang, Songyuan Luo, Yuan Liu, Wenhui Huang, Nianjin Xie, Jie Li, Changjiang Yu, Xiaoping Fan, Ruixin Fan, Jiyan Chen, Jianfang Luo
Journal: Journal of the American College of Cardiology (2017)
The draft genome of tropical fruit durian (Durio zibethinus)
Authors: Bin Tean Teh, Kevin Lim, Chern Han Yong, Cedric Chuan Young Ng, Sushma Ramesh Rao, Vikneswari Rajasegaran, Weng Khong Lim, Choon Kiat Ong, Ki Chan, Vincent Kin Yuen Cheng, Poh Sheng Soh, Sanjay Swarup, Steven G Rozen, Niranjan Nagarajan, Patrick Tan
Journal: Nature Genetics (2017)

The assembly of the durian genome provides insights into the unique flavor profile of this tropical fruit. Transcriptome and metabolome analyses show that methionine γ-lyase is upregulated and that volatile sulfur compounds are produced during ripening. Durian (Durio zibethinus) is a Southeast Asian tropical plant known for its hefty, spine-covered fruit and sulfury and onion-like odor. Here we present a draft genome assembly of D. zibethinus, representing the third plant genus in the Malvales order and first in the Helicteroideae subfamily to be sequenced. Single-molecule sequencing and chromosome contact maps enabled assembly of the highly heterozygous durian genome at chromosome-scale resolution. Transcriptomic analysis showed upregulation of sulfur-, ethylene-, and lipid-related pathways in durian fruits. We observed paleopolyploidization events shared by durian and cotton and durian-specific gene expansions in MGL (methionine γ-lyase), associated with production of volatile sulfur compounds (VSCs). MGL and the ethylene-related gene ACS (aminocyclopropane-1-carboxylic acid synthase) were upregulated in fruits concomitantly with their downstream metabolites (VSCs and ethylene), suggesting a potential association between ethylene biosynthesis and methionine regeneration via the Yang cycle. The durian genome provides a resource for tropical fruit biology and agronomy.
Surgical quality and the impact of liver resection on outcome in the new EPOC study
Authors: S. Pugh, J. Bridgewater, M. Finch-Jones, M. Rees, D. O'Reilly, M. Peterson, B. Davidson, R. Hutchins, N. Heaton, L.R. Jiao, S. Mudan, A. Allen, J. Mellor, G. Griffiths, D. Cunningham, T. Maughan, J. Garden, J. Primrose
Journal: Annals of Oncology (2017)
Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia
Authors: Stephen B. Kennedy, Fatorma Bolay, Mark Kieh, Greg Grandits, Moses Badio, Ripley Ballou, Risa Eckes, Mark Feinberg, Dean Follmann, Birgit Grund, Swati Gupta, Lisa Hensley, Elizabeth Higgs, Krisztina Janosko, Melvin Johnson, Francis Kateh, James Logue, Jonathan Marchand, Thomas Monath, Martha Nason, Tolbert Nyenswah, François Roman, Eric Stavale, Julian Wolfson, James D. Neaton, H. Clifford Lane
Journal: New England Journal of Medicine (2017)

The safety and efficacy of vaccines to prevent Ebola virus disease (EVD) were unknown when the incidence of EVD was peaking in Liberia.We initiated a randomized, placebo-controlled, phase 3 trial of the chimpanzee adenovirus 3 vaccine (ChAd3-EBO-Z) and the recombinant vesicular stomatitis virus vaccine (rVSV∆G-ZEBOV-GP) in Liberia. A phase 2 subtrial was embedded to evaluate safety and immunogenicity. Because the incidence of EVD declined in Liberia, the phase 2 component was expanded and the phase 3 component was eliminated.A total of 1500 adults underwent randomization and were followed for 12 months. The median age of the participants was 30 years; 36.6% of the participants were women. During the week after the administration of vaccine or placebo, adverse events occurred significantly more often with the active vaccines than with placebo; these events included injection-site reactions (in 28.5% of the patients in the ChAd3-EBO-Z group and 30.9% of those in the rVSV∆G-ZEBOV-GP group, as compared with 6.8% of those in the placebo group), headache (in 25.1% and 31.9%, vs. 16.9%), muscle pain (in 22.3% and 26.9%, vs. 13.3%), feverishness (in 23.9% and 30.5%, vs. 9.0%), and fatigue (in 14.0% and 15.4%, vs. 8.8%) (P<0.001 for all comparisons); these differences were not seen at 1 month. Serious adverse events within 12 months after injection were seen in 40 participants (8.0%) in the ChAd3-EBO-Z group, in 47 (9.4%) in the rVSV∆G-ZEBOV-GP group, and in 59 (11.8%) in the placebo group. By 1 month, an antibody response developed in 70.8% of the participants in the ChAd3-EBO-Z group and in 83.7% of those in the rVSV∆G-ZEBOV-GP group, as compared with 2.8% of those in the placebo group (P<0.001 for both comparisons). At 12 months, antibody responses in participants in the ChAd3-EBO-Z group (63.5%) and in those in the rVSV∆G-ZEBOV-GP group (79.5%) remained significantly greater than in those in the placebo group (6.8%, P<0.001 for both comparisons).A randomized, placebo-controlled phase 2 trial of two vaccines that was rapidly initiated and completed in Liberia showed the capability of conducting rigorous research during an outbreak. By 1 month after vaccination, the vaccines had elicited immune responses that were largely maintained through 12 months. (Funded by the National Institutes of Allergy and Infectious Diseases and the Liberian Ministry of Health; PREVAIL I ClinicalTrials.gov number, NCT02344407 .).
A GINECO phase II study of Navitoclax (ABT 263) in women with platinum resistant/refractory recurrent ovarian cancer (ROC)
Authors: P.E. Brachet, M. Fabbro, A. Leary, J. Medioni, P. Follana, A. Lesoin, J-S. Frenel, S. Abadie Lacourtoisie, A. Floquet, L. Gladieff, B. You, C. Gavoille, E. Kalbacher, M. Briand, P-A. Just, C. Blanc-Fournier, A. Leconte, J. Lequesne, L. Poulain, F. Joly Lobbedez
Journal: Annals of Oncology (2017)
Association of single nucleotide polymorphisms with efficacy in nivolumab-treated NSCLC patients
Authors: E.A. Basak, S. Bins, S. El Bouazzaoui, S.L.W. Koolen, E. Oomen-De Hoop, C. van der Leest, A.A.M. van der Veldt, S. Sleijfer, R. Debets, R.H.N. van Schaik, R.H.J. Mathijssen, J.G.J.V. Aerts
Journal: Annals of Oncology (2017)
Targeting MCL1 and BCL2 in diffuse large B-cell lymphoma.
Authors: Lingxiao Li, Praechampoo Pongtornpipat, Soyoung Park, Jonathan Harry Schatz
Journal: Journal of Clinical Oncology (2014)

e19509 Background: Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin’s lymphoma. About 60% of DLBCL cases are curable with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) treatment, but most patients who fail up-front therapy will die from the disease. DLBCL can be divided into two main cell-of-origin subtypes, the germinal center B-cell-like (GCB) and the activated B-cell-like (ABC) subtype, which carries a worse prognosis. Up to a third of DLBCL tumors show simultaneous overexpression of the oncogenic transcription factor MYC and the anti-apoptotic protein BCL2. These cases, mainly of the ABC subtype, have lower response rates to R-CHOP, carrying a 5 year overall survival of ~40% versus ~70% for cases that lack MYC-BCL2 co-expression. Dinaciclib is a cyclin-dependent kinase (CDK) inhibitor that has been evaluated in Phase I and II trials for treatment of leukemias and multiple myeloma. It is a potent and specific inhibitor of CDK 1, 2, 5, 9, and can lead to down-regulation of the anti-apoptotic protein MCL1. Methods: In vitro cell viability assays, in vivo tumor generation and treatment, Western blot assays quantifying gene expression Results: We found that dinaciclib is potent in vitro against most DLBCL lines tested. Immunoblotting showed the drug works through CDK9-dependent effects. In xenograft experiments, dinaciclib dramatically slowed tumor growth and prolonged overall survival. We also employed a genetically defined immunocompetent model of MYC-BCL2 DLBCL but found the drug was much less effective both in vitro and in vivo. We hypothesized that the antitumor effects of MCL1 loss are thwarted by high expression of BCL2. We therefore combined dinaciclib with ABT-199, a BH3-mimetic inhibitor of BCL2. We found all DLBCL cells, including those that are insensitive to dinaciclib as a single agent, are highly sensitive to either ABT-199 alone or to the dinaciclib-ABT-199 combination. Conclusions: Both MCL1 and BCL2 are commonly expressed in DLBCL. Our data suggest simultaneous targeting of these functionally redundant antiapoptotic factors will be a highly effective strategy in this disease and may lead to improved outcomes for high-risk patients, including those with MYC-BCL2 co-expression.
GW28-e1230 Tranvenous cardiac implantable electronic device implantation in patients with persistent left superior vena cava in a tertiary center
Authors: Xueying Chen, Ziqing Yu, Jin Bai, Wei Wang, Shengmei Qin, Jingfeng Wang, Zhe Sun, Fei Han, Yangang Su, Junbo Ge
Journal: Journal of the American College of Cardiology (2017)
TOPK phosphorylation of histone H2AX prevents arsenite-induced apoptosis in RPMI7951 melanoma cells
Authors: Tatyana Zykova, Feng Zhu, Chengrong Lu, LeeAnn Higgins, Yasuaki Tatsumi, Yasuhito Abe, Ann Bode, Zigang Dong
Journal: Cancer Research (2008)

2707  A novel mitogen activated protein kinase kinase- (MAPKK)-like protein kinase, T-LAK cell-originated protein kinase (TOPK), is expressed in a wide range of cancer cells. However, the functional details of this kinase are still unknown. We used LC/MS/MS analysis to show that TOPK can bind with histone H2AX. Phosphorylation of histone H2AX is often associated with the response to DNA damage and DNA repair is known to proceed less efficiently in the absence of histone H2AX. Arsenic is a well-documented carcinogen that also appears to be a valuable therapeutic tool in cancer treatment. Several reports have demonstrated that arsenic can induce DNA damage. Low to moderate concentrations of arsenic, which have little or no effect on normal melanocytes, may induce apoptosis of human melanomas. Here, we provided evidence that TOPK binds with and phosphorylates histone H2AX in vitro. TOPK is expressed in RPMI7951 human melanoma cells and arsenite (As3+) induced phosphorylation of TOPK (Thr9) and H2AX (Ser139) in a dose- and time-dependent manner in these cells. An immunofluorescence experiment showed that after treatment with As3+, phosphorylated TOPK co-localized with phosphorylated histone H2AX in the nucleus of RPMI7951 cells. Further, TOPK siRNA cells exhibited a decreased phosphorylation of histone H2AX with As3+ treatment. These data suggested that TOPK can phosphorylate histone H2AX in RPMI7951 cells after treatment with As3+. In addition, apoptosis was decreased in H2AX-deficient cells and increased in TOPK siRNA cells with As3+ treatment. Our results showed that TOPK binds with histone H2AX and inhibits As3+-induced apoptosis through its phosphorylation of histone H2AX. We analyzed As3+-induced apoptosis in 4 melanoma cell lines, which express different levels of TOPK and showed that cell lines expressing high levels of TOPK are more resistant to As3+-induced apoptosis. Therefore, inhibition of TOPK activity may be helpful in the treatment of melanoma with As3+.
The prognostic role of high mobility group box protein-1 in glioblastoma and its relationship with the inflammatory response
Authors: M. Yildirim, D. Süren, A.S. Alikanoğlu, Ö. Çakın, İ.A. Karacay, C. Sezer, V. Kaya, A. Güzel
Journal: Annals of Oncology (2017)
Metastatic neuroendocrine neoplasia (mNEN) treatments in over 70 years (y) old patients: A retrospective outcome analysis
Authors: A. Bongiovanni, F. Foca, F. Recine, V. Fausti, N. Riva, E. Setola, M. Faedi, A. Ianniello, F. Pieri, R. Galassi, D. Cavaliere, A. Gardini, A. Tartaglia, V. Lunedei, L. Mercatali, D. Amadori, T. Ibrahim
Journal: Annals of Oncology (2017)
Abstract 572: Hyperglycemia and Poor Outcomes in Patients without Diabetes Mellitus in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS): A Propensity Matched Analysis
Authors: Prakash C Deedwania, Bertram Pitt, Enrique V Carbajal, Ali Ahmed
Journal: Circulation (2008)

Background: The effect of hyperglycemia on outcomes in patients with acute MI (AMI) and low LVEF without diabetes mellitus is not well known. Methods: In the EPHESUS trial, of the 4411 non-DM patients, 554 had baseline hyperglycemia (≥140 mg/dL). Propensity scores for hyperglycemia were calculated for each of the 4411 patients based on 63 baseline covariates, and a greedy 1:8 matching protocol was used to match 400 and 2542 patients respectively with and without hyperglycemia. Matched Cox regression models were used to estimate associations between hyperglycemia and outcomes during 16 months of follow up. Results: Patients with hyperglycemia were more likely to be older, have higher heart rate, lower LVEF, and receive nitrates, statins, digoxin, loop diuretics, and PTCA during index admission. Unadjusted hazard ratios {HR} and 95% confidence intervals {CI} for hyperglycemia were: all-cause death (1.51; 1.22–1.87; P&lt;0.001), cardiovascular (CV) death (1.52; 1.21–1.90; P&lt;0.001), heart failure (HF) death (2.19, 1.46–3.29; P&lt;0.001), all-cause hospitalization (1.23; 1.08–1.40; P=0.002), CV hospitalization (1.51, 1.24–1.84; P&lt;0.001) and HF hospitalization (1.75; 1.37–2.25; P&lt;0.001). In the matched cohort, hyperglycemia was significantly associated with CV death (HR=1.25, 95%CI=1.01–1.54; P=0.039), sudden cardiac death (HR=1.33; 95%CI=1.02–1.73, P=0.035) and fatal/nonfatal AMI (HR=1.53, 95%CI=1.07–2.19; P=0.04; Figure ). Conclusions: In non-diabetic post-AMI HF patients, hyperglycemia is a poor prognosticator and is associated with increased risk of fatal and non-fatal AMI, CV death, HF deaths, sudden cardiac death, and CV hospitalization. Figure Fatal or non fatal acute myocardial infarction (AMI) by baseline serum glucose in post-AMI patients with no known history of diabetes mellitus
Stroma-Based Activation of pSTAT3Y705 Confers Resistance to FLT3 Inhibitors in FLT3 ITD-Positive AML
Authors: Ami Patel, Anthony D. Pomicter, Anna M. Eiring, Than Hein, William L. Heaton, Thomas O'Hare, Michael W. Deininger
Journal: Blood (2016)
Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients
Authors: Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Yee-Kit Tse, Grace Chung-Yan Lui, Kelvin Long-Yan Lam, Henry Lik-Yuen Chan
Journal: Journal of Hepatology (2017)